Iovance Biotherapeutics Inc
IOVA3.970USD
+0.840+26.84%
Close 07/23, 16:00（ET）Quotes delayed by 15 min
1.33BMarket Cap
LossP/E TTM
More Details of Iovance Biotherapeutics Inc Company
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Company Info
Ticker SymbolIOVA
Company nameIovance Biotherapeutics Inc
IPO dateJun 20, 2008
Founded at2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
Number of employees838
Security typeOrdinary Share
Fiscal year-endJun 20
Address825 Industrial Road
CitySAN CARLOS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94070
Phone16502607120
Websitehttps://www.iovance.com/
Ticker SymbolIOVA
IPO dateJun 20, 2008
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Matthew W Rosinack
Mr. Matthew W Rosinack
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
48.52M
98.37%
Rest of world
804.00K
1.63%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, May 20
Updated: Tue, May 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Shareholders
Shareholders
Proportion
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.17%
Investment Advisor/Hedge Fund
20.36%
Hedge Fund
12.89%
Private Equity
11.13%
Venture Capital
8.50%
Research Firm
4.03%
Bank and Trust
0.57%
Pension Fund
0.57%
Individual Investor
0.37%
Other
18.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
643
273.27M
81.83%
-26.86M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Quogue Capital L.L.C.
28.07M
8.4%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
27.73M
8.3%
+243.44K
+0.89%
Mar 31, 2025
MHR Fund Management LLC
24.42M
7.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
6.15%
+368.21K
+1.83%
Mar 31, 2025
Perceptive Advisors LLC
12.71M
3.81%
-9.40M
-42.51%
Mar 31, 2025
State Street Global Advisors (US)
11.04M
3.31%
-1.21M
-9.86%
Mar 31, 2025
Long Focus Capital Management LLC
9.25M
2.77%
+4.12M
+80.24%
Mar 31, 2025
Hood River Capital Management LLC
9.22M
2.76%
+224.47K
+2.50%
Mar 31, 2025
Soleus Capital Management, L.P.
7.79M
2.33%
+1.23M
+18.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.97M
1.79%
+96.88K
+1.65%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.48%
iShares Genomics Immunology and Healthcare ETF
1.06%
WisdomTree BioRevolution Fund
0.53%
SPDR S&P Biotech ETF
0.13%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
Strive Small-Cap ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.48%
iShares Genomics Immunology and Healthcare ETF
Proportion1.06%
WisdomTree BioRevolution Fund
Proportion0.53%
SPDR S&P Biotech ETF
Proportion0.13%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Strive Small-Cap ETF
Proportion0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
